Asprosin impairs insulin secretion in response to glucose and viability through TLR4/JNK-mediated inflammation

This report suggests asprosin as a novel therapeutic target for the treatment of type 2 diabetes through preservation of β-cell function.Graphical abstract
Source: Molecular and Cellular Endocrinology - Category: Endocrinology Source Type: research